Cite
HARVARD Citation
Gaudio, E. et al. (n.d.). Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas. Annals of oncology. pp. 1123-1128. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Gaudio, E. et al. (n.d.). Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas. Annals of oncology. pp. 1123-1128. [Online].